The OPTIFAST total and partial meal replacement programme reduces cardiometabolic risk in adults with obesity: Secondary and exploratory analysis of the OPTIWIN study
Authors' conclusion
In people with obesity at low ASCVD risk, OP significantly reduced cardiovascular risk factors and 10-year predicted risk for ASCVD.
Study context
- Population
- Men and women with obesity, BMI 30–55 kg/m², age 18–70 years, not on anti-obesity medications
- Participants
- 135 vs 138
- Comparison
- OPTIFAST total then partial meal replacement programme vs low-calorie food-based dietary plan, both within comprehensive lifestyle intervention
- OPTIFAST (OP)n = 135
- Food-based (FB)n = 138reference
Methodological detailssecondary and exploratory analysis, 52-week
- Secondary and exploratory analysis
- 52-week
Primary result
BP ≤130/80 mmHg achieved · week 26
Odds ratio
2.11
95% CI 1.10–4.03
P = 0.024
As reported in the abstract
Further findings
| Outcome | OP | FB | P value |
|---|---|---|---|
| Weight loss (parent OPTIWIN result) · week 26 | −12.4% | −6.0% | P < 0.001 |
| Weight loss (parent OPTIWIN result) · week 52 | −10.5% | −5.5% | P < 0.001 |
BP, lipids and 10-year atherosclerotic cardiovascular disease (ASCVD) risk · 52 weeks
- Similar but slightly attenuated pattern at 52 weeks
Subgroups (age, baseline SBP, sex): SBP, DBP and ASCVD risk
- Greater reductions with OP vs FB generally seen with quantitatively higher baseline SBP and age, and in men
Original publication
The OPTIFAST total and partial meal replacement programme reduces cardiometabolic risk in adults with obesity: Secondary and exploratory analysis of the OPTIWIN study. Diabetes Obes Metab. Published 11 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →